Antifungal Drugs Market: Global Market Size, Dynamics, Regional Share, Trends, Competitor Analysis 2016 to 2021 and Forecast 2022 to 2028

$ PRICE - $ 3,000.00$ 8,900.00

Antifungal Drugs Market: By Drug Class (Azoles, Polyenes, Echinocandins, Allylamines, Others), Route of Administration (Oral, Parenteral, Topical), Therapeutic Indications (Aspergillosis, Candidiasis, Dermatophytosis, Others), Distribution Channel (Retail pharmacies, Hospital pharmacies, Drug stores, Online pharmacies) and Geography

 

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail
SKU: N/A Categories: ,

Report

Description

Antifungal Drugs Market size is valued at USD 15,623.8 million in 2021 and is expected to grow at a CAGR of 3.9% during the forecast period 2022 to 2028. The global market provides a detailed overview and that can be segmented by drug type, by route of administration, by Therapeutic indication, and by distribution channel. By drug type, the Antifungal Drugs market growth has been segmented into Azoles, Polyenes, Echinocandins, Allylamines, and Others. The Azoles segment is likely to be the largest and fastest-growing segment in terms of drug type. Azoles are used to treat candidemia, blastomycosis, ocular fungal infections, and systemic candidiasis. It helps in fungistatic activities by hindering fungal enzymes. Azoles are also utilized in the treatment of systemic fungal infections, divided into imidazoles and triazoles. They provide an extensive spectrum of activity along with improved safety levels. Triazoles have less severe effects, fewer serious drug interactions, and enhanced distribution and absorption properties. The above-mentioned advantages of the use of azoles are attributed to the antifungal drug market share. Based on the Route of administration, the Antifungal Drugs market is segmented into Oral, Parenteral, and Topical. Among these, the Topical route of administration segment is expected to have a significantly growing market during the forecast period 2022-2028. Based on the Therapeutic indication, the Antifungal Drugs market is segmented into Aspergillosis, Candidiasis, Dermatophytosis, and Others. The Candidiasis segment is expected to have a significant share in 2021. Candidiasis is the most frequently happening systemic fungal infection. It is a yeast infection by the genus Candida. Its process to cure has changed over time. Some of the variations comprise suitable usage of broad-spectrum azoles and echinocandins for treatment of candidemia, invasive candidiasis, and mucosal candidiasis. Based on the distribution channel, the Antifungal Drugs market is segmented into Retail pharmacies, Hospital pharmacies, Drug stores, and Online pharmacies.

Key Development:

In June 2021, Mankind Pharma launched Posaconazole Gastro which was a tablet for drug resistance.

In June 2021, Cadila Pharmaceuticals launched Posaconazole which can be used against an extensive range of fungal disorders.

Antifungal Drugs Market

MARKET SUMMARY
-
3.9%
  • Study Period– 2022-2028
  • Base Year– 2021
  • CAGR– 3.9%
  • Largest Market– North America
  • Fastest Growing Market– Europe

Antifungal Drugs Market

  • The report on global antifungal drugs market gives historical, current, and future market sizes (US$ Mn) on the basis of drug class, route of administration, therapeutic indications, distribution channel and geography.
  • The antifungal drugs market report gives comprehensive outlook across the region with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America and Middle East and Africa
Key Players
  • Pfizer, Inc. (U.S.)
  • Novartis AG (Switzerland)
  • Sanofi (France)
  • Merck & Co., Inc. (U.S.)
  • Enzon Pharmaceuticals, Inc. (U.S.)
Antifungal Drugs Market Drivers

The growing incidences of nosocomial and fungal infections are anticipated to propel the market growth over the forecast years. Moreover, the growing healthcare expenditure, which helps in refining its infrastructure, is burgeoning the market growth over the forecast years.


North-America got significant share

Antifungal Drugs Market

North America holds the largest share in the antifungal drugs market followed by Europe and Asia-Pacific, owing to increasing patient awareness, R&D expenditure for development of new drugs, and increase in prevalence rate of fungal infections in U.S. (According to Centre for Disease Control and Prevention (CDC) approximately 46,000 new cases of candidiasis occur every year in U.S.) Europe holds a major market share in anti-fungal drugs market attributed to increase in the prevalence rate of fungal infections in Europe and the development of antifungal biopharmaceuticals. Asia Pacific accounts for a significant growth owing to burgeoning consumer base and development in the economies of China and India. Rising income per capita, increasing awareness about the personal hygiene, and increase in healthcare expenditure might fuel the antifungal drugs market in Asia-Pacific region.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Features of the Report

  • The report provides granular level information about the market size, regional market share and forecast
  • The report covers in-detail insights about the competitor’s overview, key findings and their key strategies
  • The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
  • The report tracks recent innovations, key developments and startup’s details that are working in the industry
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
Antifungal Drugs Market Segmentation


Location

GEOGRAPHY

Frequently Asked Questions

According to CDC, in 2017, about 23,000 cases of invasive candidiasis were recorded.

The growth in the use of nanotechnology in the formulation of innovative antifungal drugs

The rise in the number of developing markets and the increasing number of drug launches and approvals.

The high price related to the antifungals and the growing population with antifungal drug resistance and the absence of healthcare infrastructure in developing countries.


Report

Table Of Content

1. Executive Summary

2. Global Anti fungal Drugs Market Introduction

2.1. Global Anti fungal Drugs Market – Taxonomy

2.2. Global Anti fungal Drugs Market –Definitions

2.2.1. Drug Class

2.2.2. Route of Administration

2.2.3. Therapeutic Indications

2.2.4. Distribution Channel

3. Global Anti fungal Drugs Market Dynamics

3.1. Drivers

3.2. Restraints

3.3. Opportunities/Unmet Needs of the Market

3.4. Trends

3.5. Global Anti fungal Drugs Market Dynamic Factors – Impact Analysis

3.6. Global Anti fungal Drugs Market – Competition Landscape

3.7. Epidemiology

4. Global Anti fungal Drugs Market Analysis,2013 – 2017 and Forecast, 2018 – 2024

4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

4.3. Market OpportunityAnalysis

5. Global Anti fungal Drugs Market, By Drug Class, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

5.1. Azoles

5.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.1.3. Market Opportunity Analysis

5.2. Polyenes

5.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.2.3. Market Opportunity Analysis

5.3. Echinocandins

5.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.3.3. Market Opportunity Analysis

5.4. Allylamines

5.4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.4.3. Market Opportunity Analysis

5.5. Others

5.5.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.5.3. Market Opportunity Analysis

6. Global Anti fungal Drugs Market Forecast, By Route of Administration, 2013 – 2017 and Forecast, 2017 – 2024

6.1. Oral

6.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.1.3. Market Opportunity Analysis

6.2. Parenteral

6.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.2.3. Market Opportunity Analysis

6.3. Topical

6.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.3.3. Market Opportunity Analysis

7. Global Anti fungal Drugs Market Forecast, By Therapeutic Indications, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

7.1. Aspergillosis

7.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

7.1.3. Market Opportunity Analysis

7.2. Candidiasis

7.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

7.2.3. Market Opportunity Analysis

7.3. Dermatophytosis

7.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

7.3.3. Market Opportunity Analysis

7.4. Others

7.4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

7.4.3. Market Opportunity Analysis

8. Global Anti fungal Drugs Market Forecast, By Distribution Channel, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

8.1. Retail pharmacies

8.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

8.1.3. Market Opportunity Analysis

8.2. Hospital pharmacies

8.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

8.2.3. Market Opportunity Analysis

8.3. Drug stores

8.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

8.3.3. Market Opportunity Analysis

8.4. Online pharmacies

8.4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

Market Opportunity Analysis

9. Global Anti fungal Drugs Market Forecast, By Region, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

9.1. North America

9.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

9.1.3. Market Opportunity Analysis

9.2. Europe

9.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

9.2.3. Market Opportunity Analysis

9.3. Asia-Pacific

9.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

9.3.3. Market Opportunity Analysis

9.4. Latin America

9.4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

9.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

9.4.3. Market Opportunity Analysis

9.5. Middle East and Africa

9.5.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

9.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

9.5.3. Market Opportunity Analysis

9.6. Global Anti fungal Drugs Market – Opportunity Analysis Index, By Drug Class, By Route of Administration, By Therapeutic Indications, By Distribution Channel, and Region, 2018 – 2024

10. North America Anti fungal Drugs MarketAnalysis,2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

10.1. Drug ClassAnalysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)

10.1.1. Azoles

10.1.2. Polyenes

10.1.3. Echinocandins

10.1.4. Allylamines

10.1.5. Others

10.2. Route of Administration Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

10.2.1. Oral

10.2.2. Parenteral

10.2.3. Topical

10.3. Therapeutic Indications Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

10.3.1. Aspergillosis

10.3.2. Candidiasis

10.3.3. Dermatophytosis

10.3.4. Others

10.4. Distribution Channel Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

10.4.1. Retail pharmacies

10.4.2. Hospital pharmacies

10.4.3. Drug stores

10.4.4. Online pharmacies

10.5. Country Analysis 2016 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

10.5.1. U.S.

10.5.2. Canada

10.6. North America Anti fungal Drugs Market – Opportunity Analysis Index, By Drug Class, By Route of Administration, By Therapeutic Indications, By Distribution Channel, and Region, 2018 – 2024

10.7. North America Anti fungal Drugs Market Dynamics – Trends

11. Europe Anti fungal Drugs Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

11.1. Drug Class Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)

11.1.1. Azoles

11.1.2. Polyenes

11.1.3. Echinocandins

11.1.4. Allylamines

11.1.5. Others

11.2. Route of Administration Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

11.2.1. Oral

11.2.2. Parenteral

11.2.3. Topical

11.3. Therapeutic Indications Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

11.3.1. Aspergillosis

11.3.2. Candidiasis

11.3.3. Dermatophytosis

11.3.4. Others

11.4. Distribution Channel Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

11.4.1. Retail pharmacies

11.4.2. Hospital pharmacies

11.4.3. Drug stores

11.4.4. Online pharmacies

11.5. Country Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

11.5.1. Germany

11.5.2. UK

11.5.3. France

11.5.4. Spain

11.5.5. Italy

11.5.6. Russia

11.5.7. Poland

11.5.8. Rest of Europe

11.6. Europe Anti fungal Drugs Market – Opportunity Analysis Index, By Drug Class, By Route of Administration, By Therapeutic Indications, By Distribution Channel, and Region, 2018 – 2024

11.7. Europe Anti fungal Drugs Market Dynamics – Trends

12. Asia-Pacific Anti fungal Drugs Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

12.1. Drug Class Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)

12.1.1. Azoles

12.1.2. Polyenes

12.1.3. Echinocandins

12.1.4. Allylamines

12.1.5. Others

12.2. Route of Administration Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

12.2.1. Oral

12.2.2. Parenteral

12.2.3. Topical

12.3. Therapeutic Indications Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

12.3.1. Aspergillosis

12.3.2. Candidiasis

12.3.3. Dermatophytosis

12.3.4. Others

12.4. Distribution Channel Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

12.4.1. Retail pharmacies

12.4.2. Hospital pharmacies

12.4.3. Drug stores

12.4.4. Online pharmacies

12.5. Country Analysis2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

12.5.1. Japan

12.5.2. China

12.5.3. India

12.5.4. ASEAN

12.5.5. Australia & New Zealand

12.5.6. Rest of Asia-Pacific

12.6. Asia-Pacific Anti fungal Drugs Market – Opportunity Analysis Index, By Drug Class, By Route of Administration, By Therapeutic Indications, By Distribution Channel, and Region, 2018 – 2024

12.7. Asia-Pacific Anti fungal Drugs Market Dynamics – Trends

13. Latin America Anti fungal Drugs Market Analysis, 2012 – 2012 – 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

13.1. Drug Class Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)

13.1.1. Azoles

13.1.2. Polyenes

13.1.3. Echinocandins

13.1.4. Allylamines

13.1.5. Others

13.2. Route of Administration Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

13.2.1. Oral

13.2.2. Parenteral

13.2.3. Topical

13.3. Therapeutic Indications Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

13.3.1. Aspergillosis

13.3.2. Candidiasis

13.3.3. Dermatophytosis

13.3.4. Others

13.4. Distribution Channel Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

13.4.1. Retail pharmacies

13.4.2. Hospital pharmacies

13.4.3. Drug stores

13.4.4. Online pharmacies

13.5. Country Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

13.5.1. Brazil

13.5.2. Mexico

13.5.3. Argentina

13.5.4. Venezuela

13.5.5. Rest of Latin America

13.6. Latin America Anti fungal Drugs Market – Opportunity Analysis Index, By Drug Class, By Route of Administration, By Therapeutic Indications, By Distribution Channel, and Region, 2018 – 2024

13.7. Latin America Anti fungal Drugs Market Dynamics – Trends

14. Middle East and Africa Anti fungal Drugs Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

14.1. Drug Class Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)

14.1.1. Azoles

14.1.2. Polyenes

14.1.3. Echinocandins

14.1.4. Allylamines

14.1.5. Others

14.2. Route of Administration Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

14.2.1. Oral

14.2.2. Parenteral

14.2.3. Topical

14.3. Therapeutic Indications Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

14.3.1. Aspergillosis

14.3.2. Candidiasis

14.3.3. Dermatophytosis

14.3.4. Others

14.4. Distribution Channel Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

14.4.1. Retail pharmacies

14.4.2. Hospital pharmacies

14.4.3. Drug stores

14.4.4. Online pharmacies

14.5. Country Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

14.5.1. Gulf Cooperation Council (GCC) Countries

14.5.2. Israel

14.5.3. South Africa

14.5.4. Rest of MEA

14.6. MEA Anti fungal Drugs Market – Opportunity Analysis Index, By Drug Class, By Route of Administration, By Therapeutic Indications, By Distribution Channel, and Region, 2018 – 2024

14.7. MEA Anti fungal Drugs Market Dynamics – Trends

15. Competition Landscape

15.1. Strategic Dashboard of Top Market Players

15.2. Company Profiles (Introduction, Financial Analysis, Drug Class& Service Offerings, Key Developments, Strategies, and SWOT Analysis)

15.2.1. Pfizer, Inc. (U.S.)

15.2.2. Novartis AG (Switzerland)

15.2.3. Sanofi (France)

15.2.4. Merck & Co., Inc. (U.S.)

15.2.5. Enzon Pharmaceuticals, Inc. (U.S.)

15.2.6. Bayer AG (Germany)

15.2.7. Astellas Pharma, Inc. (Japan)

15.2.8. GlaxoSmithKline plc. (U.K.)

15.2.9. Mylan N.V. (U.S.), Tecan Group (Switzerland)

15.2.10. AureoGen Biosciences Inc. (U.S.)

16. Research Methodology

17. Key Assumptions and Acronyms


Report

Company Profile

  • Pfizer, Inc. (U.S.)
  • Novartis AG (Switzerland)
  • Sanofi (France)
  • Merck & Co., Inc. (U.S.)
  • Enzon Pharmaceuticals, Inc. (U.S.)
  • Bayer AG (Germany)
  • Astellas Pharma, Inc. (Japan)
  • GlaxoSmithKline plc. (U.K.)
  • Mylan N.V. (U.S.)
  • Tecan Group (Switzerland)
  • AureoGen Biosciences Inc. (U.S.)

Description

Antifungal Drugs Market size is valued at USD 15,623.8 million in 2021 and is expected to grow at a CAGR of 3.9% during the forecast period 2022 to 2028. The global market provides a detailed overview and that can be segmented by drug type, by route of administration, by Therapeutic indication, and by distribution channel. By drug type, the Antifungal Drugs market growth has been segmented into Azoles, Polyenes, Echinocandins, Allylamines, and Others. The Azoles segment is likely to be the largest and fastest-growing segment in terms of drug type. Azoles are used to treat candidemia, blastomycosis, ocular fungal infections, and systemic candidiasis. It helps in fungistatic activities by hindering fungal enzymes. Azoles are also utilized in the treatment of systemic fungal infections, divided into imidazoles and triazoles. They provide an extensive spectrum of activity along with improved safety levels. Triazoles have less severe effects, fewer serious drug interactions, and enhanced distribution and absorption properties. The above-mentioned advantages of the use of azoles are attributed to the antifungal drug market share. Based on the Route of administration, the Antifungal Drugs market is segmented into Oral, Parenteral, and Topical. Among these, the Topical route of administration segment is expected to have a significantly growing market during the forecast period 2022-2028. Based on the Therapeutic indication, the Antifungal Drugs market is segmented into Aspergillosis, Candidiasis, Dermatophytosis, and Others. The Candidiasis segment is expected to have a significant share in 2021. Candidiasis is the most frequently happening systemic fungal infection. It is a yeast infection by the genus Candida. Its process to cure has changed over time. Some of the variations comprise suitable usage of broad-spectrum azoles and echinocandins for treatment of candidemia, invasive candidiasis, and mucosal candidiasis. Based on the distribution channel, the Antifungal Drugs market is segmented into Retail pharmacies, Hospital pharmacies, Drug stores, and Online pharmacies.

Key Development:

In June 2021, Mankind Pharma launched Posaconazole Gastro which was a tablet for drug resistance.

In June 2021, Cadila Pharmaceuticals launched Posaconazole which can be used against an extensive range of fungal disorders.

ASIA PACIFIC OFFICE

Precision Business Insights, MIG 366, SAI PLAZA, 1st Floor, KPHB Colony, Hyderabad - 500072

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX